Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Bioblast Editor | Jun 19, 2025
On 19 June 2025, Australia’s Therapeutic Goods Administration (TGA) updated its online list of prescription medicines for evaluation for March, April and May 2025.
Among the applications to be reviewed is MSD’s clesrovimab (MK-1654, approved on 9 June 2025 as Enflons...
By Pearce IP | Jun 19, 2025
Four Pearce IP leaders have been included in World IP Review (WIPR) Leaders 2025. WIPR Leaders provides a research driven global guide to the top intellectual property lawyers acro...
By Pearce IP | Jun 19, 2025
We are thrilled to share that Pearce IP was awarded DEI: Outstanding Firm at the Chambers Asia-Pacific and Greater China Region Awards 2025 gala in Singapore on 30 May.
For ...
By Naomi Pearce, Chantal Savage | Jun 17, 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 13 June 2025 are set out below:...
By Bioblast Editor | Jun 17, 2025
On 17 June 2025, Regeneron filed a new BPCIA complaint against Amgen in the United States District Court for the Central District of California, asserting that Amgen’s Pavblu™/ABP 938 (aflibercept) infringes US 12,331,099, which claims an ophthalmic formulation of afliberce...
By Pearce IP | Jun 16, 2025
Pearce IP has been recognised for the first time by Managing IP Stars for trade mark prosecution in its 2025 Trade Mark rankings.
In addition to Pearce IP’s existing ranking f...
By Pearce IP | Jun 16, 2025
We are thrilled to announce that 6 Pearce IP patent professionals have again been recognised by Managing IP in the 2025 MIP IP STARS, a leading global guide to the top intellectual ...
By Bioblast Editor | Jun 16, 2025
On 16 June 2025, Celltrion announced that the FDA has approved a new single-dose 45mg/0.5mL subcutaneous injection of Steqeyma® (CT-P43), biosimilar to J&J/Janssen’s Stelara® (ustekinumab). The new presentation is approved for the treatment of paediatric patients aged ...
By Bioblast Editor | Jun 16, 2025
On 16 June 2025, Korea Biomedical Review reported that the Dusseldorf Higher Regional Court ruled that Samsung Bioepis/Biogen’s Imraldi®, biosimilar to AbbVie’s Humira® (adalimumab), infringes a formulation patent held in Germany by Fresenius Kabi. The Fresenius patent, E...
By Pearce IP | Jun 13, 2025
Firm & 6 Leaders ranked in AU & NZ, for Patent Litigation & Prosecution
Pearce IP and 6 of its leaders have been ranked in Australia and New Zealand for patent lit...
SUBSCRIBE TO PEARCE IP
Copyright © 2026 Pearce IP. All Rights Reserved. Privacy Statement